Item 8.01 Other Events.
E-Qure Corp., a Delaware corporation, OTCQB: EQUR (the "Company"), a medical
device Company, reported today the following material updates regarding
Bioelectrical Signal Therapy device ("BST Device) developed for the treatment of
wounds via electrical stimulation, which is believed to result in accelerated
wound healing by imitating the natural electrical current that occurs in injured
skin on the human body. Our BST Device stimulates renewed blood flow and oxygen
in order to induce local cell regeneration and therefore promote wound healing.
1. The Company has been granted with the Helsinki committee approval of Clalit
Health Services Organization, Israel's largest HMO, and the Israeli Ministry of
Health (MOH) to launch a Randomized Control Study (RCT) on 60-100 patients in
order to assess the efficacy of the BST Device on diabetic foot patients. The
study will be performed in 3-5 sites including leading clinics and hospitals in
Israel. The Company intends to enroll the first patients to the study during the
next 2-3 weeks and expects the trial to be conducted for 12-18 months until
completion.
2. The Company has concluded a 35-wound, one arm clinical pilot, treating
recalcitrant wounds in a leading wound clinic in Tel Aviv Israel, with 78% of
the treated wounds completely healed within 20 weeks (Avg. wound duration at the
base was 8 months) and an additional 16% of the treated wounds reaching wound
area reduction of greater than 75%. Only 6% of the patients had no substantial
positive clinical effect.
3. The Company recently filed a provisional patent with United States Patent and
Trademark Office for the purpose of protecting the main features of our
proprietary unique electrical healing signal BST Device.
4. The Company's distributor in Colombia, TekMedica SAS, has successfully
concluded a clinical pilot study at the Hospital de la Samaritana in Bogota,
Colombia. Starting in January 2020, Colsanitas, a leading Colombian HMO/Health
insurance provider and operator of comprehensive healthcare services in Colombia
and a member of the Sanitas group worldwide, will commence a clinical pilot
study which is expected to be concluded by the end of the first half of 2020. If
positive results are achieved, similar to those achieved in the Tel Aviv
clinical trials, the Company believes that it will contribute to the penetration
of the BST device treatment with Colsanitas health services in Colombia.
© Edgar Online, source Glimpses